XML 67 R50.htm IDEA: XBRL DOCUMENT v3.8.0.1
Selected Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Data (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2016
Sep. 30, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract]                      
Revenues $ 43,562 [1] $ 35,578 [1] $ 30,475 [1] $ 15,286 [1] $ 11,962 [1] $ 5,268 [1] $ 97 [1] $ 4 [1] $ 124,901 [1] $ 17,331 [1] $ 61
Gross profit [2] 41,107 33,443 28,251 13,023 10,258 4,423 (429)   115,824 14,252  
Net loss $ (68,871) $ (65,248) $ (67,441) $ (87,843) $ (78,696) $ (71,613) $ (71,322) $ (49,762) $ (289,403) $ (271,393) $ (164,443)
Basic and diluted net loss per share $ (0.55) [3] $ (0.53) [3] $ (0.55) [3] $ (0.72) [3] $ (0.65) [3] $ (0.61) [3] $ (0.63) [3] $ (0.45) [3] $ (2.36) [3] $ (2.34) [3] $ (1.63)
[1] The Company commenced commercial sales of NUPLAZID in May 2016. The quarters after March 31, 2016 reflect net product revenue related to NUPLAZID.
[2] Determined by subtracting cost of product sales from product sales, net.
[3] Net loss per common share, basic and diluted, are computed independently for each quarter and the full year based upon respective average shares outstanding. Therefore, the sum of the quarterly net loss per common share amounts may not equal the annual amounts reported.